Anti-cd30l antibodies and uses thereof
US-2024254246-A1 · Aug 1, 2024 · US
US9109033B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9109033-B2 |
| Application number | US-201314135292-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2013 |
| Priority date | Dec 12, 1997 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo. Preferably, the method of the present invention results in increasing immune response towards the antigen in the animal.
Opening claim text (preview).
What is claimed is: 1. A method of treating an immune system related condition in a subject, the method comprising administering an antibody or a binding fragment thereof to a subject in need thereof, wherein said antibody or binding fragment thereof is specific for a human form of TRANCE and not a mouse form of TRANCE and binds to a human TRANCE polypeptide, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:2. 2. The method of claim 1 , w…
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.